SCYNEXIS to Participate in September Investor Conferences

About this update from Scynexis, Inc.

[{"type":"text","content":"JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences. Event:H.C. Wainwright 25th Annual Global Investment ConferenceFormat:Company presentation and 1-on-1 meetingsDate:September 12th, 2023Time:9:00 A.M. E.T.Location:New York, NYRegistration:Link Event:Cantor Fitzgerald Global Healthcare ConferenceFormat:Fireside chat and 1-on-1 meetingsDate:September 28th, 2023Time:1:50 P.M. E.T.Location:New York, NYRegistration:Link About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing its proprietary class of enfumafungin-derived antifungal compounds (“fungerps\") as broad-spectrum, systemic antifungal agents for multiple fungal indications. The U.S. Food and Drug Administration (FDA) approved the first representative of this antifungal class, BREXAFEMME® (ibrexafungerp tablets), in June 2021 for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022 for reduction in the incidence of recurrent VVC. Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections is ongoing. Additional assets in the novel “fungerp” class of antifungals are currently in pre-clinical and discovery phase, including the compound SCY-247. For more information, visit www.scynexis.com. CONTACT: Investor RelationsIrina KofflerLifeSci AdvisorsTel: (646) [email protected] \nSource: Scynexis","length":5388,"tagName":"div"}]

More updates from Scynexis, Inc.